Drug Profile
Research programme: rheumatoid arthritis therapeutics - Biogen
Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Reata Pharmaceuticals
- Developer Biogen
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis